Showing 8431-8440 of 8647 results for "".
- Practice-Hospital Consolidation Increasing for Many Specialtieshttps://modernod.com/news/practice-hospital-consolidation-increasing-for-many-specialties/2480021/The level of integration of certain primary care practices into health systems and hospitals more than doubled in recent years, with steeper increases seen in the fields of oncology and cardiology, according to research publish
- Zeiss Names New Chief Financial Officerhttps://modernod.com/news/zeiss-names-news-chief-financial-officer/2480025/Christian Müller, PhD, will become Chief Financial Officer of Carl Zeiss AG, succeeding Thomas Spitzenpfeil who, as previously announced, will leave the company. Dr. Müller has been CFO of the Zeiss subsidiary Carl Zeiss Meditec AG since 2009. He joined the Zeiss Group in 2002 as head of Corporat
- Study: Combined Cataract Surgery Ups Postop Endophthalmitis Riskhttps://modernod.com/news/study-combined-cataract-surgery-ups-postop-endophthalmitis-risk/2480042/Patients who undergo combined cataract surgery, or removal of cataracts combined with treatment of other eye disorders during the same procedure, have higher incidence of acute postoperative endophthalmitis (acute POE) compared with those who have cataract surgery alone, results of a French natio
- Quantel Medical Introduces Vitra 2: Retinal Photocoagulation Simplifiedhttps://modernod.com/news/quantel-medical-introduces-vitra-2-retinal-photocoagulation-simplified/2480043/Quantel Medical said it has reinvented its flagship 532nm green photocoagulator with the introduction of the Vitra 2. The Vitra 2 features a new generation of optimized laser cavity with an increased max power
- Cataract Surgery Tied to Lower Risk of Car Crasheshttps://modernod.com/news/cataract-surgery-tied-to-lower-risk-of-car-crashes/2480048/Drivers with cataracts who get surgery to have them removed may lower their risk of getting into traffic crashes, a recent study suggests, according to a Reuters Health report. Compared to their chances of a crash before surgery, dr
- Ocugen Initiates Phase 3 Clinical Trial of OCU300 for the Treatment of Ocular Graft Versus Host Diseasehttps://modernod.com/news/ocugen-initiates-phase-3-clinical-trial-of-ocu300-for-the-treatment-of-ocular-graft-versus-host-disease/2480053/Ocugen announced that it has initiated the first of two pivotal, phase 3 clinical trials of OCU300 for the treatment of ocular discomfort and ocular redness in patients with ocular graft versus host disease (oGVHD) following recent acceptance of Ocugen’s investigational new drug (IND) appli
- Lin BioScience Receives EMA Orphan Drug Status for LBS-008 for the Treatment of Stargardt Diseasehttps://modernod.com/news/lin-bioscience-receives-ema-orphan-drug-status-for-lbs-008-for-the-treatment-of-stargardt-disease/2480056/Lin BioScience announced that the European Medicines Agency has granted orphan drug designation to LBS-008, a first-in-class oral therapy for the treatment of Stargardt Disease. Stargardt Disease is currently an untreatable inherited condition that causes permanent vision loss in children
- Former P&G And Cincinnati Children’s Executive Katherine Overbey Joins OneSight As President And Executive Directorhttps://modernod.com/news/former-pg-and-cincinnati-childrens-executive-katherine-overbey-joins-onesight-as-president-and-executive-director/2480057/Global vision care nonprofit OneSight announced that Katherine “K-T” Overbey will be joining the organization as President and Executive Director. Ms. Overbey brings a distinct blend of blue-chip corporate and nonprofit experience in both developed and emerging markets, as well as a s
- Oyster Point Pharma Gets Green Light From FDA to Proceed With Clinical Development of Dry Eye Treatmenthttps://modernod.com/news/oyster-point-pharma-gets-green-light-from-fda-to-proceed-with-clinical-development-of-dry-eye-treatment/2480060/Oyster Point Pharma announced that the FDA has cleared the company’s investigational new drug (IND) application to proceed with clinical development of OC-01, an investigational compound intended to stimulate natural tear film production in people with dry eye disease that is administered with a
- Market Scope: OCT Market to Generate $632 Million in Revenues in 2018https://modernod.com/news/market-scope-oct-market-to-generate-632-million-in-revenues-in-2018/2480062/Market Scope estimates that the optical coherence tomography (OCT) market will generate $632 million in total manufacturer revenues in 2018, and the market will grow to $797 million by 2023 at a compound annual growth rate of 4.8 percent. Market Scope expects much of this growth to come fr